Lexicon Pharmaceuticals, Inc. (LXRX) Position Held by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado held its position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,364 shares of the biopharmaceutical company’s stock at the end of the first quarter. Public Employees Retirement Association of Colorado’s holdings in Lexicon Pharmaceuticals were worth $177,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in LXRX. 361 Capital LLC bought a new position in Lexicon Pharmaceuticals during the first quarter valued at $186,000. C WorldWide Group Holding A S raised its position in Lexicon Pharmaceuticals by 2.5% in the first quarter. C WorldWide Group Holding A S now owns 11,677 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 280 shares during the last quarter. DUPONT CAPITAL MANAGEMENT Corp bought a new position in Lexicon Pharmaceuticals during the first quarter valued at $519,000. Old Mutual Global Investors UK Ltd. raised its position in Lexicon Pharmaceuticals by 38.2% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 421,242 shares of the biopharmaceutical company’s stock valued at $6,040,000 after buying an additional 116,513 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. raised its position in Lexicon Pharmaceuticals by 33.3% in the first quarter. Candriam Luxembourg S.C.A. now owns 260,000 shares of the biopharmaceutical company’s stock valued at $3,729,000 after buying an additional 65,000 shares during the last quarter.

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) opened at 17.04 on Tuesday. The stock’s 50 day moving average price is $15.45 and its 200-day moving average price is $15.06. The firm’s market cap is $1.79 billion. Lexicon Pharmaceuticals, Inc. has a 52-week low of $13.01 and a 52-week high of $19.62.

WARNING: “Lexicon Pharmaceuticals, Inc. (LXRX) Position Held by Public Employees Retirement Association of Colorado” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/2654452/lexicon-pharmaceuticals-inc-lxrx-position-held-by-public-employees-retirement-association-of-colorado.html.

LXRX has been the topic of a number of research analyst reports. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. BidaskClub raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, June 14th. HC Wainwright set a $27.00 price target on Lexicon Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $21.00 price target on shares of Lexicon Pharmaceuticals in a research report on Wednesday, April 5th. Finally, Citigroup Inc. raised their price target on Lexicon Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, March 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. Lexicon Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $26.67.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:LXRX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.